|Title:||Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy||Authors:||Yeh, Ting Kuang
Jean, Shio Shin
Lee, Yu Lin
Lu, Min Chi
Ko, Wen Chien
Lin, Hsueh Ju
Liu, Po Yu
|Keywords:||Antimicrobial | Bacteriophage therapy | CRISPR-Cas | Phage-based vector;Antimicrobial; Bacteriophage therapy; CRISPR-Cas; Phage-based vector||Issue Date:||1-Jan-2021||Source:||International Journal of Antimicrobial Agents||Abstract:||
Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.